FDA offers Novartis a thumbs-up on Enbrel biosimilar as Amgen plays offense/defense simultaneously
On Friday, the FDA gave Amgen a clean bill of health for its biosimilar of AbbVie’s Humira. Today, it’s Amgen’s turn to watch a megablockbuster …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
